The Leukemia & Lymphoma Society's (LLS's) academic grants support and encourage basic and translational leukemia, lymphoma and myeloma research.
LLS investigators are outstanding scientists at the forefront of leukemia, lymphoma and myeloma research at centers throughout the world. We award academic grants for studies that range from basic blood cancer research to research that uses the latest tools of genomics.
And we don't stop there. We're also dedicated to funding blood cancer research to help improve the quality of life for patients and their families with our projects studying long-term and late effects.
The Translational Research Program (TRP) puts you on the bench-to-bedside fast track when it comes to finding better treatment and cures for leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application. TRP 2018-2019 Guidelines & Instructions for Applying...
The Leukemia & Lymphoma Society's (LLS) Career Development Program (CDP) provides support so that you can devote yourself to researching questions of direct relevance to hematological malignancies and/or relevant pre-malignant conditions. LLS offers career development awards to postdoctoral fellows and instructors, as well as early career, independent investigators. Please verify in our Guidel...
The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and/or optimization of small molecules ...
LLS’s Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or p...
The Rising Tide Foundation for Clinical Cancer Research and the Leukemia & Lymphoma Society partner in an international competitive grant to advance breakthroughs in prevention for blood cancers. The grant is focused on addressing four critical topics and is endowed with a total of USD $3 million. The LLS does not currently plan to reopen this program. The grants must be t...
The Leukemia & Lymphoma Society is proud to announce the fourth year of The New Idea Award, a grant program designed to identify novel research strategies with a potential for high impact on blood cancer. Specifically, this program supports the initial exploration of untested but potentially transformative ideas that challenge our knowledge of blood cancer or the manner in which we approach diagnosis or tre...
The Leukemia & Lymphoma Society (LLS) announces a competitive grant program to benefit mantle cell lymphoma (MCL) patients. This is a milestone-driven research program with an overarching goal to move discoveries quickly from the bench to the clinic. The program is intended to bring together at least 3 independent research projects that are integrated and supported by scientific cores. Inter-institutional or intr...
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a private foundation in Switzerland, is focused on funding promising, innovative translational studies and clinical trials that hold the promise of delivering hopeful, encouraging and immediate options for cancer patients to prevent, diagnose, treat or improve quality of life. In a joint collaboration, the RTFCCR and LLS aim to s...
The Leukemia & Lymphoma Society (LLS) is proud to announce the "Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers," a new Request for Proposals (RFP) to identify and develop novel, safe and effective treatment paradigms for patients with hematological malignancies. LLS is very pleased that Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson &...
2017 Request for Proposals
The MPN Challenge grant application process is NOW CLOSED. The Leukemia & Lymphoma Society (LLS) is partnered with the MPN Research Foundation (MPNRF) to support a grant program whose objective is to change the trajectory and ultimate prognosis for patients with myeloproliferative neoplasms, particularly myelofibrosis, polycythemia vera and essential thrombocythemia. The MPN Challenge program represents ...
LLS has formed a partnership with Celgene to create the first of such RFPs that will build the foundation of this new LLS initiative. This initiative will identify and fund priority research areas, with support from biotech and pharmaceutical partners in order to address significant unmet medical needs. The near-term goal of this program is to advance the scientific and medical understanding of the various hematologi...
